4Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. E- valuation, treatment, and prevention of vitamin D defi- ciency: an Endocrine Society clinical practice guideline [Jl- J Clin Endocrinol Metab, 2011, 96: 1911-1930.
5Binkley N, Wiebe D. Clinical controversies in vitamin D: 25OHD measurement, target concentration, and supple- mentation [J]. J Clin Densitomet, 2013, 16: 402-408.
6Xie Z, Zhang Z, Liao E, et al. High prevalence of vita- min D insufficiency and deficiency among postmenopausal women in China: Preliminary Results of a Chinese Multi- center Study [ C 1. The American Society for Bone and Mineral Research (ASBMR) Annual Meeting, 2014.
7Wang Q, Lu C, Xu Y, et al. Prevalence of vitamin D de- ficiency in women who live with lowest sunshine: an epide- miological study in Sichuan, China [ C 1. 7th International Conference on Osteoporosis and Bone Research, 2014.
8Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [J]. Kidney Int, 2009, 113: $1-130.
9Almond A, Ellis AR, Walker SW, et al. Current para- thyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease [ J]. Ann Clin Biochemist, 2012, 49: 63-67.
10Liao E. FGF23 associated bone diseases [ J]. Front Med, 2013, 7: 65-80.
